In laboratory studies, the active component of honeybee venom rapidly killed two types of breast cancer cells that are particularly difficult to treat. Crucially, the toxin left healthy cells unharmed.

For thousands of years, humans have used honey, propolis, and venom from the European honeybee Apis mellifera as medicines.

More recently, scientists have discovered that honeybee venom and its active component, melittin, are toxic to a wide range of tumors — including melanoma, lung, ovarian, and pancreatic cancers — in laboratory tests.

Melittin is the molecule that creates the painful sensation of a bee’s sting. Scientists do not fully understand how it kills cancer cells, however.

For the first time, researchers have investigated the effect of melittin and honeybee venom on a range of breast cancers, including two of the most aggressive and hard-to-treat types.

Breast cancer is the most common cancer in women. The two aggressive types, known as triple-negative breast cancer and HER2-enriched breast cancer, are associated with the poorest outcomes. They tend to develop resistance to existing treatments.

Scientists at the Harry Perkins Institute of Medical Research in Perth, Australia, and the University of Western Australia, also in Perth, found that melittin and honeybee venom rapidly kill these cancer types, with negligible effects on normal cells.

“The venom was extremely potent,” says Dr. Ciara Duffy, who led the research. “We found that melittin can completely destroy cancer cell membranes within 60 minutes.”

The study also showed that venom from bumblebees, which contains no melittin, did not kill the cancer cells — even at high concentrations.

The study authors note that honeybee venom is relatively cheap and easily obtainable, making it a good option for cancer treatment in countries with poorly resourced health services.

They write:

“Honeybee venom is available globally and offers cost effective and easily accessible treatment options in remote or less developed regions. Further research will be required to assess whether the venom of some genotypes of bees has more potent or specific anticancer activities, which could then be exploited.”

This line of research is in its infancy, with researchers yet to perform clinical trials in humans to assess the safety and efficacy of melittin for treating breast cancer.

Although this particular study found no evidence of harm to noncancerous cells, other studies suggest otherwise. Therefore, healthcare professionals may need to carefully target melittin to tumors to prevent collateral damage to healthy tissue.

Medical reference: Medical News Today